A photothermal driven motor microneedle containing sinomenine and total glycosides of white paeony for treating rheumatoid arthritis and a preparation method thereof

By designing a photothermal drive motor microneedle loaded with cyperine and pyrolysine, using the FAPEG-modified silicon nanobottle and perfluorohexane gasification driving mechanism, the active targeted delivery and prolonged retention of the drug's joint cavity is achieved. , solve the problems of drug instability and difficulty in targeted joint delivery in the prior art, and improve the effectiveness and safety of treatment.

CN117338922BActive Publication Date: 2024-11-19ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202311207145.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-19
Publication Date
2024-11-19
Estimated Expiration
2043-09-19

AI Technical Summary

Technical Problem

Among the existing treatment methods for rheumatoid arthritis, the total glycoside of leucorrhea and leucorrhea are limited in treatment effects and are accompanied by adverse reactions due to instability, easy decomposition and low bioavailability. It is difficult to achieve traditional administration methods. The joint targeted delivery of drugs and prolonged retention at joint sites.

Method used

A photothermal drive motor microneedle carrying cyperine and leucoriae is designed. Through the FAPEG-modified silicon nanobottle and perfluorohexane gasification driving mechanism, the drug is promoted by using near-infrared light to promote drug release and distribution to achieve drug Active targeted delivery of the joint cavity site to enhance retention at the inflammatory site.

Benefits of technology

It improves the transdermal characteristics and safety of the drug, significantly improves the retention amount and treatment effect at joint sites, reduces the occurrence of adverse reactions, and enhances the bioavailability of the drug and the effectiveness of clinical treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117338922B_ABST
    Figure CN117338922B_ABST
Patent Text Reader

Abstract

The present invention provides a sinomenine and white peony total glucosides photothermal driven motor microneedle for treating rheumatoid arthritis, so as to improve the subcutaneous local tissue drug delivery efficiency of percutaneous administration, thereby improving the effectiveness of SIN and TGP in clinical treatment of RA and patient compliance; at the same time, a method for preparing the above-mentioned novel skin delivery preparation is provided; comprising the following contents: a sinomenine and white peony total glucosides photothermal driven motor microneedle for treating rheumatoid arthritis, comprising the following components: 300-500 parts of FAPEG-modified silicon nanobottle, 3-4 parts of sinomenine hydrochloride, 12-16 parts of white peony total glucosides, 5-30 parts of perfluorohexane, 5-10 parts of indocyanine green, 100-200 parts of tetradecanol, and 1-10 parts of pure water.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical preparations for external use on skin, and in particular relates to a sinomenine and white paeony total glucosides photothermal driven motor microneedle and a preparation method thereof. Background Art

[0002] Rheumatoid arthritis (RA) is a chronic immune-mediated disease that primarily affects the synovium of the joints. During the course of RA, the synovium transforms into a proliferative, invasive tissue, leading to the destruction of cartilage and bone, accompanied by severe joint pain. Its patient population accounts for approximately 0.5%-2% of the global population, bringing a heavy burden to both individual patients and society.

[0003] In recent years, traditional Chinese medicine has attracted much attention for its significant efficacy and fewer side effects in the treatment of rheumatoid arthritis, and has been widely used in clinical practice. Commonly used Chinese medicines in clinical practice include Sinomenium acutum, Millettia reticulata, Caulis sansevieriae, Paeonia lactiflora, Cinnamomum cassiae, Scorpio, Centipede, Achyranthes bidentata, Gentiana macrophylla, Astragalus, Phellodendron chinense, and Tripterygium wilfordii. Sinomenine (SIN) is an alkaloid monomer extracted from Sinomenium acutum (thunb.) Rehd. et Wils. or Sinomenium scutum (Thunb.) Rehd. et Wils. var. cinereum Rehd. et Wils. of the Menispermaceae family. It has anti-arthritis, anti-apoptosis and immunosuppressive effects. In addition, SIN can also induce mesenchymal stem cells to inhibit the formation of osteoclasts and reduce osteoclast activating factor in fibroblast-like synoviocytes to protect arthritis bone damage. However, the clinical application of SIN in the treatment of RA is still largely limited. The reason is that SIN has adverse reactions such as rash, leukopenia, anaphylactic shock and severe gastrointestinal reactions. And because SIN itself is easy to decompose, unstable to alkali, light and heat, and has a short biological half-life, low bioavailability, and a small amount of drug reaching the lesion site after circulation, clinical treatment often requires long-term and high-dose use. Therefore, while obtaining the effective therapeutic effect of SIN, reducing adverse reactions is an important prerequisite for expanding its clinical use.

[0004] At present, the ways and methods of reducing toxicity and increasing efficacy of Sinomenium sinomenium include controlling the source of toxicity reduction, processing toxicity reduction and efficacy reduction, Chinese medicine compatibility toxicity reduction and efficacy reduction, Western medicine compatibility toxicity reduction and efficacy reduction, modern biotechnology structure modification toxicity reduction and efficacy reduction, and changing the dosage form and route of administration. In the combination of Chinese medicine, white peony root, black shun tablets, radix chuanxiong, and compound medicines such as Qingbai Tongbi Capsule, CQ Pain Relief Compound, and Wuteng Powder are commonly used. Among them, the combination of white peony root and sinomenine is more common. Total glucosides of paeonia (TGP) is a general term for a mixture of physiologically effective ingredients obtained from the dried roots of white peony root, of which paeoniflorin accounts for more than 90% of the total amount, and has multiple effects such as analgesia, anti-inflammatory, immunomodulation, and protection of liver function. Clinical studies have found that TGP is effective in treating RA and can slow down the destruction of joints and cartilage by inhibiting the abnormal proliferation of synovial cells. It can also improve liver function, has few adverse reactions, is safe and reliable, and is an ideal slow-acting anti-rheumatic drug. Clinical medication has found that the combined use of sinomenine and white peony root can not only increase the efficacy of the drug but also reduce the toxicity and adverse reactions that occur during traditional medication, especially significantly reducing the incidence of liver damage and epigastric discomfort, and has a good protective effect on the patient's liver function.

[0005] Transdermal drug delivery (TDD) refers to a route of delivering drugs through the skin at a fixed dose and adjustable rate to produce local or systemic therapeutic effects. Compared with oral and injection administration, TDD can avoid the first-pass effect of the liver and drug absorption is not affected by factors such as pH, food and other drugs in the gastrointestinal tract; at the same time, TDD has a controlled release effect, which can maintain the therapeutic concentration of the drug, prolong the drug action time, avoid adverse reactions caused by excessive blood drug concentration due to excessive absorption, and significantly improve patient compliance and acceptability. With the continuous development of drug delivery needs and materials, processes and equipment, researchers have developed various technologies for TDD after system theory and penetration-promoting methods, including ion introduction, electroporation, thermal ablation, microdermabrasion, cavitation ultrasound and the addition of chemical penetration enhancers. The above strategies have improved the transdermal permeability of macromolecular drugs to a certain extent, but its development is still in its early stages, and there are problems to be solved, such as the safety of the method, the practicality of the drug delivery device, and the adaptability of the patient.

[0006] Microneedles (MNs) are minimally invasive devices consisting of needle arrays of about 50-900 μm in length. They are manufactured through microfabrication technology of different materials and geometric shapes. MNs can deliver drugs to the subepidermis and bypass the stratum corneum barrier. Therefore, compared with traditional injection and oral drug delivery strategies, microneedle drug delivery is safe, convenient, and painless, and can easily overcome the stratum corneum barrier to achieve drug delivery. Dissolvable microneedles (DMNs) do not leave needle fragments under the skin, minimizing the risk of inflammation caused by foreign bodies. Studies have found that drug-loaded soluble microneedle patches can avoid the first-pass metabolism of drugs in the liver and gastrointestinal toxicity, and can release drugs stably and for a long time; however, although the microneedle transdermal route can avoid the safety issues caused by joint cavity injection to a certain extent, increase the transdermal absorption of drugs and improve patient compliance, it does not have the advantages of joint-targeted drug delivery, and it also cannot avoid the rapid lymphatic clearance of drugs in the joints. Therefore, it is necessary to further design drug delivery carriers to achieve targeted delivery of drugs and prolong retention in the inflammatory site of the joint cavity. In recent years, the research and development of nanopharmaceutical preparations for combating RA has surged, with the aim of making up for the shortcomings of current treatment methods. Systems based on active targeted delivery of nanoparticles (NPs) have the potential to improve the localization of drugs in cartilage. Nanomotors (NM) are a new type of self-driven nanoscale device. Due to the advantages of small size, autonomous movement and remote non-contact control, nanomotors have great potential for application in the biomedical field. Among them, photothermal-driven nanomotors that do not require fuel have received a lot of attention. Since photothermal motors are reversible, wireless and remotely controlled, and can achieve power on / off functions by controlling light irradiation, they have obvious advantages over ordinary nanomotors in in vivo applications. Compared with ordinary nanomotors, photothermal motors can achieve effective self-propulsion in biological fluids, have high drug loading, are not restricted by fuel, have low toxicity, and have strong drug loading capacity. Therefore, this project intends to design a photothermal-driven nanomotor drug delivery system to achieve active targeted drug delivery in the RA joint cavity.

[0007] In summary, this project builds a microneedle drug delivery system with photothermal-driven nanomotors loaded with SIN and TGP based on the high expression of folic acid in the RA joint cavity and the mobility of photothermal-driven nanomotors. Soluble microneedles are used for transdermal delivery to enable nanomotors to penetrate the skin, and then folic acid and photothermal-driven motors are used to target the RA joint cavity, thereby reducing adverse reactions and enhancing the retention of drugs in the inflammatory site, achieving the purpose of increasing efficacy and reducing toxicity. Summary of the invention

[0008] The purpose of the present invention is to provide a photothermal-driven motor microneedle containing sinomenine and total glucosides of white paeony for the treatment of rheumatoid arthritis in view of the shortcomings of existing preparations, so as to improve the efficiency of transdermal drug delivery to subcutaneous local tissues, thereby improving the effectiveness of SIN and TGP in the clinical treatment of RA and patient compliance; another purpose of the present invention is to provide a method for preparing the above-mentioned new skin drug delivery preparation.

[0009] A photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized by comprising the following components:

[0010] 300-500 parts of FAPEG-modified silicon nanobottle, 3-4 parts of sinomenine hydrochloride, 12-16 parts of total glycosides of white paeony, 5-30 parts of perfluorohexane, 5-10 parts of indocyanine green, 100-200 parts of tetradecanol, and 1-10 parts of pure water.

[0011] A photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that the FAPEG-modified silicon nanobottle is obtained by reacting (3-chloropropyl)trimethoxysilane and butyl orthosilicate with FAPEG-silane.

[0012] A method for preparing a photothermal-driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that it comprises the following steps:

[0013] Step 1: Prepare a silicon nanobottle by reacting (3-chloropropyl)trimethoxysilane and butyl orthosilicate;

[0014] Step 2, reacting FAPEG-silane with the nanobottle to generate FAPEG-modified silicon nanobottle;

[0015] Step 3, sinomenine hydrochloride, total glucosides of white peony, tetradecanol, perfluorohexane, and indocyanine green are loaded into the FAPEG-modified silicon nanobottle to obtain a photothermal driven motor loaded with sinomenine and total glucosides of white peony;

[0016] Step 4: Evenly mix the photothermal driven motor containing sinomenine and total glucosides of white peony with the microneedle matrix and pour them into the microneedle mold, and dry them to obtain the photothermal driven motor microneedles containing sinomenine and total glucosides of white peony.

[0017] A method for preparing a photothermal-driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that the volume ratio of (3-chloropropyl)trimethoxysilane to butyl orthosilicate is 1:10, the molecular weight of the FAPEG-silane is 2000, the weight ratio of sinomenine hydrochloride, total glucosides of white paeony, tetradecanol, perfluorohexane, indocyanine green and FAPEG-modified silicon nanobottle is 0.4:1.6:20:50:1:40, and the concentration of the hyaluronic acid matrix is ​​100 mg / mL.

[0018] A method for preparing a photothermal-driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that the steps of preparing a silicon nanobottle by reacting (3-chloropropyl)trimethoxysilane and butyl orthosilicate are specifically as follows:

[0019] Step 1: Weigh a certain amount of polyvinyl pyrrolidone and dissolve it in n-pentanol, add citric acid ammonium solution and anhydrous ethanol, and vortex;

[0020] Step 2: Add a certain amount of (3-chloropropyl)trimethoxysilane and butyl orthosilicate, vortex, then ultrasonicate, and react under stirring at room temperature;

[0021] Step 3: After the reaction is completed, centrifuge, wash with anhydrous ethanol, and dry to obtain a silicon nanobottle.

[0022] According to claim 5, a photothermal-driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis is characterized in that the citric acid-ammonia aqueous solution is a 0.2 M citric acid-ammonia aqueous solution in which 2.58 g of citric acid is dissolved in ammonia water and then the volume is fixed to 50 mL.

[0023] A preparation method of a photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that the steps of reacting FAPEG-silane with a nanobottle to form a FAPEG-modified silicon nanobottle are specifically as follows:

[0024] (1) Weighing a certain amount of the above-mentioned silicon nanobottle and dispersing it in a mixed solution of anhydrous ethanol and ammonia water;

[0025] (2) Add FAPEG-silane solution dropwise in a 50°C water bath and stir for 24 h;

[0026] (3) After the reaction is completed, the silica nanobottle is washed with anhydrous ethanol and dried to obtain the FAPEG-modified silica nanobottle.

[0027] A method for preparing sinomenine and total glucosides of white paeony photothermal driven motor microneedles for treating rheumatoid arthritis, characterized in that the FAPEG-silane solution is obtained by dissolving 2 mg FAPEG-silane in 2 mL DMSO.

[0028] A method for preparing a photothermal driven motor microneedle containing sinomenine and total glucosides of white peony for treating rheumatoid arthritis, characterized in that sinomenine hydrochloride, total glucosides of white peony, tetradecanol, perfluorohexane, and indocyanine green are loaded into a FAPEG-modified silicon nanobottle to obtain a photothermal driven motor containing sinomenine and total glucosides of white peony, and the specific steps are as follows:

[0029] Step 1: perfluorohexane is loaded into the above-mentioned FAPEG-modified silicon nanobottle by negative pressure;

[0030] Step 2, add sinomenine hydrochloride, total glucosides of white paeony, indocyanine green, tetradecanol and methanol, and stir for 30 minutes;

[0031] Step 3: Add pure water and centrifuge to wash, and then obtain the photothermal drive motor loaded with sinomenine and total glucosides of white paeony.

[0032] A method for preparing photothermal-driven motor microneedles containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that perfluorohexane is pre-treated with oxygen enrichment.

[0033] A method for preparing a photothermal driven motor microneedle containing sinomenine and total glucosides of white peony for treating rheumatoid arthritis, characterized in that the photothermal driven motor containing sinomenine and total glucosides of white peony is mixed evenly with a microneedle matrix, poured into a microneedle mold, and dried to obtain the photothermal driven motor microneedle containing sinomenine and total glucosides of white peony by the following steps:

[0034] Step 1: Dissolve hyaluronic acid in appropriate amount of ultrapure water and let stand to defoam;

[0035] Step 2: Add the above-mentioned photothermal driven motor containing sinomenine and total glucosides of white paeony into the hyaluronic acid solution and mix them evenly to obtain a drug-containing microneedle matrix;

[0036] Step 3: Add the drug-containing microneedle matrix to the PDMS mold, evacuate the mold, remove bubbles and dry it to obtain the photothermal driven motor microneedles loaded with sinomenine and total glucosides of white paeony.

[0037] A method for preparing photothermal-driven motor microneedles containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that the concentration of the hyaluronic acid solution is 100 mg / mL, the microneedle array of the microneedle PDMS mold is 10×10, and the needle tip length is 600 μm.

[0038] The sinomenine and white paeony glycosides in the invention are respectively extracted from effective parts of Chinese medicinal herbs sinomenine and white paeony root, meet the national pharmacopoeia standards, and are commercially available.

[0039] The nanocarrier in the present invention is obtained by hydrolysis polymerization of (3-chloropropyl)trimethoxysilane and butyl orthosilicate. (3-chloropropyl)trimethoxysilane can be replaced by (3-mercaptopropyl)trimethoxysilane, propyltrimethoxysilane, 1,2-bis(triethoxysilyl)ethane, etc. Butyl orthosilicate can be replaced by tetraethyl orthosilicate, tetra(2-ethylbutyl)silicate, etc.

[0040] Compared with the traditional injection and oral administration strategies, microneedle administration is safe, convenient, painless, and can easily overcome the barrier of the stratum corneum to achieve drug delivery, but it does not have the advantages of joint-targeted drug delivery of intra-articular injection, and it is also impossible to avoid the rapid lymphatic clearance of drugs at the joint site. Nanoparticle-based systems have the potential to improve the positioning of drugs in cartilage, but the dense and highly charged extracellular matrix of cartilage cells constitutes an obstacle to drug administration. Polymer nanoparticles can achieve different degrees of cartilage positioning through passive and active targeting. Active targeting uses specific biochemical properties to selectively target the inflammatory site, further improving specificity, efficiency and residence time in inflammatory cells. Therefore, FA and PEG co-modified nanocarriers are designed in the present invention to target macrophage FA receptors and improve the retention capacity of drug carriers at inflammatory sites.

[0041] Photothermally driven nanomotors have attracted much attention in recent years. They can perform reversible and repeatable motion behaviors and achieve on / off functions through radiation. Such nanomotors show obvious advantages in in vivo applications, including effective propulsion in biological fluids, high drug loading, strong drug dragging ability, and enhanced tissue retention ability. However, due to random loading, nanomotors have poor asymmetry and low thermophoretic force. In the present invention, asymmetric nanoparticles are prepared in order to obtain stronger driving force.

[0042] The present invention designs a photothermal effect-induced perfluorohexane gasification-driven nanomotor drug delivery system, which is beneficial to achieve active targeted drug delivery in the RA joint cavity.

[0043] In the present invention, indocyanine green is used as a photothermal material, and the temperature rises under near-infrared light irradiation to cause perfluorohexane to gasify.

[0044] In the present invention, the perfluorohexane saturated with oxygen generates heat and gasifies under the action of near-infrared light through photothermal material to generate microbubbles to promote the release and distribution of the drug.

[0045] The tetradecanol in the present invention is insoluble in water and is used as a bottle stopper to prevent drug leakage.

[0046] The study found that the present invention uses the photothermal effect of asymmetric nanobottles, FAPEG-silane, indocyanine green and perfluorohexane, and utilizes the transdermal drug delivery characteristics of microneedles to produce photothermal-driven motor microneedles loaded with sinomenine and total glucosides of white paeony with enhanced targeting and drug delivery. The microneedles have better transdermal properties and are safer and more compliant than traditional oral and intra-articular injections. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0048] Figure 1 Transmission electron microscopy images of nanobottles prepared under different conditions

[0049] Figure 2 Cumulative release curves of FAPEG-SNM@SIN-TGP and SNM@SIN-TGP under illumination and without illumination

[0050] Figure 3 Effects of different preparations on inflammatory factors in vitro

[0051] Figure 4 Cell apoptosis after 12h incubation with different preparations

[0052] Figure 5 Inverted fluorescence microscope and scanning electron microscope images of drug-loaded microneedles

[0053] Figure 6 Force-displacement curve of drug-loaded microneedles and microneedle strength

[0054] Figure 7 Q of SIN-TGP in ex vivo skin n -t curve, Q e -t curve

[0055] Figure 8 Drug retention of SIN-TGP in ex vivo skin DETAILED DESCRIPTION

[0056] The present invention is further described below in conjunction with specific examples. The methods are conventional methods unless otherwise specified, and the raw materials can be obtained from public commercial channels unless otherwise specified.

[0057] The evaluation methods for the particle size and particle size distribution, morphology, skin permeability, photothermal conversion and in vitro release of the sinomenine and total glycosides of white paeony photothermal motors described in the embodiments of the present invention are as follows:

[0058] 1. Particle size and its distribution evaluation method

[0059] The particle size distribution and zeta potential of FAPEG-SNM@SIN-TGP were determined by dynamic light scattering particle size analyzer.

[0060] 2. Morphological observation

[0061] Take a small amount of FAPEG-SNM@SIN-TGP and dilute it with distilled water to an appropriate mass concentration, disperse it evenly in an ultrasonic oscillator, draw a small amount of the suspension and drop it onto the copper mesh, dry it naturally, let it stand for a while to allow the nanomotor to deposit on the copper mesh, and observe the morphology and electron microscopic particle size of the nanobottle and nanomotor under a transmission electron microscope.

[0062] 3. In vitro release

[0063] The in vitro drug release characteristics of FAPEG-SNM@SIN-TGP were investigated by direct release method. The nanoparticles were dispersed in 4 mL PBS solution, sealed with Eppendroff tubes, placed in a constant temperature water oscillator at 37±0.5℃, and oscillated at 135r / min. Centrifuged (5000rpm, 5min) at 15, 30, 60, 120, 180, 240, 300, and 360min, and 1 mL of supernatant was aspirated for later use. The remaining release medium in the tube was discarded, 4 mL of release medium was added, and the oscillation in the water bath oscillator was continued. The concentrations of SIN and TGP in the release medium were determined by HPLC.

[0064] Each sample was tested in triplicate. The release curves of the illuminated group and the non-illuminated group were compared to investigate the effect of NIR illumination on the in vitro drug release of FAPEG-SNM@SIN-TGP. The laser was irradiated for 10 min at 120 min and 240 min, respectively (power 3 W / cm 2 ) to determine the changes in drug release before and after NIR irradiation.

[0065] 4. FAPEG-SNM@SIN-TGP cytotoxicity

[0066] The CCK-8 method was used to evaluate the cytotoxicity. Raw 264.7 in the logarithmic growth phase was cultured at 1×10 4Cells / well were inoculated in a 96-well plate, and blank wells were set as control wells. Cells in the blank culture medium of the scaffold were set as blank wells. Eight parallel experimental wells were set for each concentration (divided into light exposure and non-light exposure). LPS was added for activation and cultured overnight. The culture medium was discarded, and preparations containing different concentrations were added and incubated in the incubator for 4 hours. The light group was irradiated with 808nm laser for 5 minutes (3W / cm 2 ).

[0067] After the illumination, 100 μL of diluted CCK-8 solution (CCK-8: blank culture medium = 1:9) was added to each well of all groups and incubated in the incubator for 1 h. The absorbance value of each well at 450 nm was measured by an ELISA instrument, and the cell survival rate was calculated by the formula.

[0068]

[0069] 5. Pharmacodynamic evaluation at the cell level

[0070] In vitro determination of proinflammatory cytokines. RAW 264.7 cells were cultured at 1.5 × 10 5 Inoculate in each well of a 6-well plate. Then incubate at 37°C for 12h, add different dosage forms, and use PBS as a blank control. After 6h, LPS is added to the control group for activation. After 16h, collect the cell supernatant and detect its expression level, detect the content of TNF-α, IL-6 and IL-1β in the cell culture supernatant, and perform ELISA test according to the protocol of the ELISA kit.

[0071] Example 1

[0072] Blank nanoparticles (SNM-1) consist of the following components in parts by weight:

[0073]

[0074] Specifications and sources of main components: n-pentanol (AR, 98%, Shanghai McLean Reagent Co., Ltd.), polyvinyl pyrrolidone (K30, Beijing Solebow Technology Co., Ltd.), anhydrous ethanol (pharmaceutical grade, 99.5%, Shanghai McLean Reagent Co., Ltd.), (3-chloropropyl)trimethoxysilane (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), butyl orthosilicate (98%, Shanghai McLean Reagent Co., Ltd.), sodium citrate (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), ammonia water (GR, 25-28%, 35.05MW, Shanghai Aladdin Biochemical Technology Co., Ltd.).

[0075] The preparation steps of blank nanoparticles (SNM-1) are as follows:

[0076] 1) Weigh the amount of polyvinyl pyrrolidone in the formula and dissolve it in n-pentanol, add citric acid ammonium solution and anhydrous ethanol, and vortex;

[0077] 2) adding the formulated amount of (3-chloropropyl)trimethoxysilane and butyl orthosilicate, vortexing, then ultrasonicating, and reacting at room temperature with stirring for 2.5 hours;

[0078] 3) After the reaction, centrifuge and wash with anhydrous ethanol.

[0079] Example 2

[0080] Blank nanoparticles (SNM-2) consist of the following components in parts by weight:

[0081]

[0082] Specifications and sources of main components: n-pentanol (AR, 98%, Shanghai McLean Reagent Co., Ltd.), polyvinyl pyrrolidone (K30, Beijing Solebow Technology Co., Ltd.), anhydrous ethanol (pharmaceutical grade, 99.5%, Shanghai McLean Reagent Co., Ltd.), (3-chloropropyl)trimethoxysilane (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), butyl orthosilicate (98%, Shanghai McLean Reagent Co., Ltd.), sodium citrate (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), ammonia water (GR, 25-28%, 35.05MW, Shanghai Aladdin Biochemical Technology Co., Ltd.).

[0083] The preparation steps of blank nanoparticles (SNM-2) are as follows:

[0084] 1) Weigh the amount of polyvinyl pyrrolidone in the formula and dissolve it in n-pentanol, add citric acid ammonium solution and anhydrous ethanol, and vortex;

[0085] 2) adding the formulated amount of (3-chloropropyl)trimethoxysilane and butyl orthosilicate, vortexing, then ultrasonicating, and reacting at room temperature with stirring for 2.5 hours;

[0086] 3) After the reaction, centrifuge and wash with anhydrous ethanol.

[0087] Example 3

[0088] Blank nanoparticles (SNM-3) consist of the following components in parts by weight:

[0089]

[0090] Specifications and sources of main components: n-pentanol (AR, 98%, Shanghai McLean Reagent Co., Ltd.), polyvinyl pyrrolidone (K30, Beijing Solebow Technology Co., Ltd.), anhydrous ethanol (pharmaceutical grade, 99.5%, Shanghai McLean Reagent Co., Ltd.), (3-chloropropyl)trimethoxysilane (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), butyl orthosilicate (98%, Shanghai McLean Reagent Co., Ltd.), sodium citrate (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), ammonia water (GR, 25-28%, 35.05MW, Shanghai Aladdin Biochemical Technology Co., Ltd.).

[0091] The preparation steps of blank nanoparticles are as follows:

[0092] 1) Weigh the amount of polyvinyl pyrrolidone in the formula and dissolve it in n-pentanol, add citric acid ammonium solution and anhydrous ethanol, and vortex;

[0093] 2) adding the formulated amount of (3-chloropropyl)trimethoxysilane and butyl orthosilicate, vortexing, then ultrasonicating, and reacting at room temperature with stirring for 2.5 hours;

[0094] 3) After the reaction, centrifuge and wash with anhydrous ethanol.

[0095] Example 4

[0096] The composition and preparation method of the photothermal motor containing sinomenine and total glycosides of white peony root (FAPEG-SNM@SIN-TGP) are as follows:

[0097] Blank nanoparticles (SNM-2) consist of the following components in parts by weight:

[0098]

[0099] Specifications and sources of main components: n-pentanol (AR, 98%, Shanghai McLean Reagent Co., Ltd.), polyvinyl pyrrolidone (K30, Beijing Solebow Technology Co., Ltd.), anhydrous ethanol (pharmaceutical grade, 99.5%, Shanghai McLean Reagent Co., Ltd.), (3-chloropropyl)trimethoxysilane (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), butyl orthosilicate (98%, Shanghai McLean Reagent Co., Ltd.), sodium citrate (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), ammonia water (GR, 25-28%, 35.05MW, Shanghai Aladdin Biochemical Technology Co., Ltd.).

[0100] The preparation steps of blank nanoparticles are as follows:

[0101] 1) Weigh the amount of polyvinyl pyrrolidone in the formula and dissolve it in n-pentanol, add citric acid ammonium solution and anhydrous ethanol, and vortex;

[0102] 2) adding the formulated amount of (3-chloropropyl)trimethoxysilane and butyl orthosilicate, vortexing, then ultrasonicating, and reacting at room temperature with stirring for 2.5 hours;

[0103] 3) After the reaction, centrifuge and wash with anhydrous ethanol.

[0104] The folic acid modified nanoparticles (FASNM-1) are composed of the following components in parts by weight:

[0105]

[0106] Specifications and sources of the main components: FAPEG-silane (2000 molecular weight, Beijing Huawei Ruike Chemical Co., Ltd.), ammonia water (GR, 25-28%, 35.05MW, Shanghai Aladdin Biochemical Technology Co., Ltd.), anhydrous ethanol (pharmaceutical grade, 99.5%, Shanghai McLean Reagent Co., Ltd.).

[0107] The preparation steps of folic acid modified nanoparticles are as follows:

[0108] 1) Weigh the amount of nanobottles in the formula and disperse them in a mixed solution of anhydrous ethanol and ammonia water;

[0109] 2) In a 50°C water bath, add the formulated amount of FAPEG-silane solution dropwise;

[0110] 3) After the reaction is completed, wash with anhydrous ethanol.

[0111] The photothermal motor containing sinomenine and total glucosides of white peony (FAPEG-SNM@SIN-TGP) is composed of the following components in parts by weight:

[0112]

[0113] Specifications and sources of the main components: sinomenine hydrochloride (98%, Shanghai McLean Biochemical Technology Co., Ltd.), total glucosides of paeony glycosides (98%, Nantong Feiyu Biotechnology Co., Ltd.), perfluorohexane (AR, 98%, Shanghai Myrel Chemical Technology Co., Ltd.), indocyanine green (75%, Shanghai Aladdin Biochemical Technology Co., Ltd.), methanol (HPLC, Anhui Tiandi High Purity Solvent Co., Ltd.), pure water was purified by PALL ultrapure water instrument.

[0114] The preparation steps of the photothermal driven motor containing sinomenine and total glucosides of white paeony are as follows:

[0115] 1) Take the formulated amount of perfluorohexane into the nanobottle through negative pressure;

[0116] 2) Add the formulated amount of sinomenine hydrochloride, total glucosides of white paeony, indocyanine green, tetradecanol, and methanol, and stir for 30 minutes;

[0117] 3) Add a certain amount of pure water and centrifuge to wash.

[0118] Example 5

[0119] The composition and preparation method of the FAPEG-free sinomenine and total glycosides of white paeony photothermal motor (SNM@SIN-TGP) are as follows:

[0120] Blank nanoparticles (SNM-2) consist of the following components in parts by weight:

[0121]

[0122] Specifications and sources of main components: n-pentanol (AR, 98%, Shanghai McLean Reagent Co., Ltd.), polyvinyl pyrrolidone (K30, Beijing Solebow Technology Co., Ltd.), anhydrous ethanol (pharmaceutical grade, 99.5%, Shanghai McLean Reagent Co., Ltd.), (3-chloropropyl)trimethoxysilane (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), butyl orthosilicate (98%, Shanghai McLean Reagent Co., Ltd.), sodium citrate (98%, Shanghai Aladdin Biochemical Technology Co., Ltd.), ammonia water (GR, 25-28%, 35.05MW, Shanghai Aladdin Biochemical Technology Co., Ltd.).

[0123] The preparation steps of blank nanoparticles are as follows:

[0124] 1) Weigh the amount of polyvinyl pyrrolidone in the formula and dissolve it in n-pentanol, add citric acid ammonium solution and anhydrous ethanol, and vortex;

[0125] 2) adding the formulated amount of (3-chloropropyl)trimethoxysilane and butyl orthosilicate, vortexing, then ultrasonicating, and reacting at room temperature with stirring for 2.5 hours;

[0126] 3) After the reaction, centrifuge and wash with anhydrous ethanol.

[0127] The FAPEG-free sinomenine and total glycosides of white paeony photothermal motor (SNM@SIN-TGP) is composed of the following components in parts by weight:

[0128]

[0129] Specifications and sources of the main components: sinomenine hydrochloride (98%, Shanghai McLean Biochemical Technology Co., Ltd.), total glucosides of paeony glycosides (98%, Nantong Feiyu Biotechnology Co., Ltd.), perfluorohexane (AR, 98%, Shanghai Myrel Chemical Technology Co., Ltd.), indocyanine green (75%, Shanghai Aladdin Biochemical Technology Co., Ltd.), methanol (HPLC, Anhui Tiandi High Purity Solvent Co., Ltd.), pure water was purified by PALL ultrapure water instrument.

[0130] The preparation steps of the photothermal driven motor containing sinomenine and total glucosides of white paeony are as follows:

[0131] 1) Take the formulated amount of perfluorohexane into the nanobottle through negative pressure;

[0132] 2) Add the formulated amount of sinomenine hydrochloride, total glucosides of white paeony, indocyanine green, tetradecanol, and methanol, and stir for 30 minutes;

[0133] 3) Add a certain amount of pure water and centrifuge to wash.

[0134] The blank nanoparticles prepared in the above example were observed for particle size potential and morphology. Figure 1 , Table 1. The photothermal motors of sinomenine and total glycosides of white peony prepared in the above examples and the photothermal motors of sinomenine and total glycosides of white peony without FAPEG modification were investigated for in vitro release, cell pharmacology and cytotoxicity. The results are shown in Figure 2 , Figure 3 , Figure 4 .

[0135] 6. Morphological observation results of nanomotors under different conditions of citric acid ammonium aqueous solution

[0136] The results show that as the reaction time progresses, at different concentrations, the opening of the nanoparticles develops a bottleneck-like structure, and the shapes of the nanoparticles are slightly different. At a concentration of 0.18 mol / L, the bottle of SNM-1 nanoparticles is smaller, and the bottleneck connecting to the external environment is longer, forming a tadpole shape, which may affect drug loading and drug release. At a concentration of 0.2 mol / L, the bottle of SNM-2 is round, with a shorter bottleneck, similar to the shape of a flask. The shape of SNM-3 nanoparticles at 0.36 mol / L is similar to that at 0.2 mol / L, but some nanoparticles do not have a bottleneck structure.

[0137] 7. In vitro release results

[0138] Phase change materials can achieve phase change according to the change of ambient temperature, thereby achieving the purpose of controlled release of drugs. The FAPEG-SNM@SIN-TGP and SNM@SIN-TGP prepared in this study are excited by near-infrared light, and the temperature rises, causing the tetradecanol to achieve solid-liquid transformation, thereby releasing the drug. This experiment used the direct release method to investigate the release characteristics of FAPEG-SNM@SIN-TGP and SNM@SIN-TGP. The results are as follows Figure 2As shown. Under light conditions, FAPEG-SNM@SIN-TGP and SNM@SIN-TGP released 52.42±0.04% and 50.88±3.08% of the total amount of drug, respectively, at 6 h. Under no light conditions, FAPEG-SNM@SIN-TGP and SNM@SIN-TGP released 16.29±1.49% and 13.65±2.76% of the total amount of drug, respectively, at 6 h. The results show that tetradecanol can control drug release and prevent drug leakage to a certain extent.

[0139] 8. Cell-level pharmacodynamic results

[0140] Proinflammatory cytokines, such as TNF-α, IL-6, and IL-1β, play an important role in the immune-related pathogenesis of RA. Therefore, in order to preliminarily verify the in vitro anti-inflammatory ability of FAPEG-SNM@SIN-TGP and SNM@SIN-TGP, the cytokine content in the supernatant of RAW264.7 cells treated with LPS was detected using an Elisa kit. Figure 3 Based on the CCK-8 experiment, the levels of TNF-α, IL-6 and IL-1β in the supernatant of each group after LPS treatment were measured. Each treatment group was able to inhibit their increase, but there was no statistical difference between the groups, proving that SIN-TGP can also inhibit the production of inflammatory factors at a lower dosage concentration.

[0141] 9. FAPEG-SNM@SIN-TGP cytotoxicity results

[0142] The in vitro cytotoxicity of free drugs and different preparations on RAW 264.7 cells under the action of different concentrations of SIN-TGP was studied, and the biocompatibility of FAPEG-SNM@SIN-TGP and SNM@SIN-TGP and the effect of photothermal effect on cells were evaluated. After incubation for 4 h, the viability of cells in each group was detected by CCK-8 method. Figure 3D. At a concentration of 0.2 μmol / L, the cytotoxicity of SNM@SIN-TGP and FAPEG-SNM@SIN-TGP was significantly lower than that of free SIN-TGP, and the cell survival rate of SNM@SIN-TGP decreased after illumination; at a concentration of 0.4 μmol / L, there was a very significant difference between the FAPEG-SNM@SIN-TGP group and the original drug group, and the survival rate of the original drug group was less than 50%; at a concentration of 0.6 μmol / L, the survival rate of the original drug group was less than 50% and the survival rate of SNM@SIN-TGPNIR was less than 50%; at a concentration of 0.8 μmol / L, the survival rate of the original drug group was less than 40%, and the survival rate of the SNM@SIN-TGP NIR group was less than 50%; at a concentration of 1 μmol / L, the survival rates of the FAPEG-SNM@SIN-TGP, FAPEG-SNM@SIN-TGP NIR and SNM@SIN-TGP groups were 70%.

[0143] The IC50 values ​​were 0.5848 μmol / L for SNM@SIN-TGP, 0.4649 μmol / L for SNM@SIN-TGP NIR, 0.9897 μmol / L for FAPEG-SNM@SIN-TGP, 0.7902 μmol / L for FAPEG-SNM@SIN-TGP NIR, and 0.3902 μmol / L for SIN-TGP solution. The overall trend was that the higher the concentration of SIN-TGP in the preparation, the lower the cell survival rate. Illumination would cause certain damage to cells, and modification of FAPEG-silane could reduce the damage to cells caused by irradiation. These results showed that the cell viability of the unmodified FAPEG-silane preparation was significantly lower than that of the modified group under the stimulation of near-infrared light. On the other hand, it was found that the cell viability of the modified preparation under irradiation was higher than that of the unmodified group. Therefore, it was speculated that FAPEG-silane could reduce the damage to cells caused by irradiation to a certain extent. In general, the cell activity of FAPEG-silane was significantly higher than that of the unmodified preparation, indicating that it had good biocompatibility.

[0144] Table 1 Particle size, potential and particle size distribution of nanobottles prepared under different conditions

[0145]

[0146] The evaluation method of the morphology, mechanical strength and other indicators of the FAPEG-SNM@SIN-TGP microneedle was as follows:

[0147] 1. Observation of microneedle morphology

[0148] Observe the shape of the microneedles, and observe the microneedle array and morphology under a Nikon inverted fluorescence microscope; according to the requirements for scanning electron microscope inspection of samples, the microneedles were gold-sprayed and observed under a scanning electron microscope.

[0149] 2. Mechanical strength evaluation

[0150] The mechanical strength of hyaluronic acid-loaded soluble microneedles was preliminarily evaluated using a texture analyzer. The mechanical properties of the microneedles were evaluated by comparing the change in microneedle height after initial compression, recording the changes in force and displacement at each time point, and plotting a force-displacement curve.

[0151] Example 6

[0152] The composition and preparation method of the photothermal driven motor microneedle containing sinomenine and total glycosides of white paeony are as follows:

[0153] 10 copies of photothermal drive motor containing sinomenine and total glycosides of white peony

[0154] Hyaluronic acid 100 parts

[0155] 1000 parts pure water

[0156] Specifications and sources of main components: hyaluronic acid (99%, MW: 10000, Shanghai Yien Chemical Technology Co., Ltd.), pure water was purified by PALL ultrapure water instrument.

[0157] The preparation steps of the photothermal driven motor microneedle containing sinomenine and total glycosides of white paeony are as follows:

[0158] 1) taking the formulated amount of hyaluronic acid, adding an appropriate amount of pure water to dissolve, standing to defoam, and preparing a 1 mg / mL hyaluronic acid solution;

[0159] 2) adding a formulated amount of sinomenine and total glycosides of white paeony to the photothermal drive motor in the hyaluronic acid solution and mixing them evenly to obtain a drug-containing microneedle matrix;

[0160] 3) Add the drug-containing microneedle matrix to the PDMS mold, evacuate (-0.06 MPa, 10 min), remove bubbles and dry.

[0161] Example 7

[0162] The composition and preparation method of blank microneedles are as follows:

[0163] Hyaluronic acid 100 parts

[0164] 1000 parts pure water

[0165] Specifications and sources of main components: hyaluronic acid (99%, MW: 10000, Shanghai Yien Chemical Technology Co., Ltd.), pure water was purified by PALL ultrapure water instrument.

[0166] The preparation steps of blank microneedles are:

[0167] 1) taking the formulated amount of hyaluronic acid, adding an appropriate amount of pure water to dissolve, standing to defoam, and preparing a 1 mg / mL hyaluronic acid solution;

[0168] 2) Add the hyaluronic acid solution to the PDMS mold, evacuate (-0.06 MPa, 10 min), remove bubbles and dry to obtain the mold.

[0169] The morphology and mechanical strength of the photothermal driven motor microneedles containing sinomenine and total glycosides of white paeony prepared in the above examples and the blank microneedles were observed and tested. Figure 5 , Figure 6 .

[0170] 3. Microneedle morphology observation results

[0171] Under an optical microscope, the microneedles can be seen to be neatly arranged, with intact needle bodies and a conical shape. The drug-loaded microneedles (1 cm × 1 cm, 10 × 10, 600 μm) were gold-sprayed and placed under a scanning electron microscope. Figure 5 shown.

[0172] 4. Mechanical strength results

[0173] In the microneedle strength test, the probe is gradually pressed down to break the microneedle. When bending is observed in the image, such as Figure 6 The curve suddenly drops in a short time and then rises. The stress peak at this point is used as the breaking force of the microneedle, that is, the strength of the microneedle, for analysis. From the data, it can be seen that the average strength of the microneedle is 148.230±14.060gf (1.501N), proving that the microneedles made by the two-step method have the ability to penetrate the skin barrier.

[0174] The evaluation method of the microneedle delivery mechanism and other indicators of FAPEG-SNM@SIN-TGP loaded with sinomenine and total glycosides of white peony root is as follows:

[0175] 1. Ex vivo skin penetration

[0176] Male SD rats were injected intraperitoneally with 3% sodium pentobarbital. After the rats were anesthetized, the hair of the rats was shaved with an electric shaver, the skin was removed, the fat tissue and fascia were peeled off, and the skin was repeatedly washed with saline. After drying with filter paper, it was wrapped with tin foil and placed in a -80℃ refrigerator for standby use. When used, the skin wrapped in tin foil was taken out from the -80℃ refrigerator, carefully opened, the skin was taken out, and it was soaked in saline for 30 minutes before use. 20% ethanol saline was injected into the receiving chamber of the Franz diffusion cell as the receiving liquid, and the excess air in the receiving chamber was discharged by ultrasound. The drug-loaded microneedles were placed on the treated ex vivo rat skin and a certain force was applied. After 1 minute, they were fixed with medical tape. The integrity of the skin must be ensured during the treatment process. After the microneedles were dissolved, near-infrared light was irradiated for 10 minutes. After the treatment was completed, the skin was placed on a 12mL receiving chamber, with the skin stratum corneum facing up and the skin tissue facing the receiving chamber, to ensure that the effective diffusion area of ​​the skin was in contact with the liquid surface of the receiving liquid. After the microneedle fixes the supply chamber and the receiving chamber, the diffusion cell is placed on a constant temperature magnetic stirrer, and the speed is 300r / min to simulate the blood and tissue fluid circulation under the human skin, and the temperature is kept constant at (37±5)℃. After 1, 2, 4, 6, 8, 10, 12, 24, and 36 hours of transdermal permeation, all the receiving liquid is collected and placed in an evaporating dish for water bath evaporation and 1mL of methanol is added. After dissolution, it is filtered through a 0.22μm microporous filter membrane and used as a sample for content determination. After sampling, an equal amount of fresh receiving liquid is added in time. Sample analysis is performed according to the content determination chromatographic conditions.

[0177] Steady-state permeation rate (J ss ) and time lag (T lag ) calculation: for Q n The slope of the straight line obtained by linear regression of the steady-state permeability section (straight line part) in the -t curve is J ss (μg·cm -2 ·h -1 ), the time corresponding to the intersection of the straight line and the horizontal axis is T lag (h), the results are shown in Table 2.

[0178] Statistical methods: Graphpad prism software was used to perform statistical analysis on the experimental data, and One-way Anova was used. All data were expressed as mean ± standard deviation (x ± s). When P < 0.05, the difference was significant; when P < 0.01, the difference was extremely significant.

[0179] 2. Ex vivo skin retention

[0180] Blank skin sample processing: Take a blank skin sample, thaw it at room temperature, cut a 1cm 2, put it in a glass homogenizer, add 3mL of extraction solvent methanol, grind it thoroughly to get skin homogenate. Vortex it thoroughly for 1min, centrifuge it at 4℃ and 1500r / min for 20min, transfer the supernatant to a 5mL centrifuge tube, take 20L of supernatant after centrifugation, and inject it according to the content determination chromatographic conditions for analysis.

[0181] Treatment of drug-containing skin samples: After the ex vivo skin permeation test (36 hours), remove the skin, rinse the inner and outer surfaces repeatedly with saline for 5 times, and use filter paper to absorb excess water on the skin surface. Take the treated skin sample and cut it into a suitable size (same as the blank skin group, if less than 1cm 2 , blank skin was used to make up for the difference). The extraction was the same as the blank skin sample treatment, and the sampling and analysis process was the same as the in vitro skin permeation experiment.

[0182] Calculation of drug retention (Qm):

[0183] Qm is calculated as follows:

[0184] Qm=X / A

[0185] Where X is the drug retention amount (g) measured in each skin sample after 36 hours of drug application; A is the effective penetration area

[0186] Statistical methods: Same as the above-mentioned treatment method for ex vivo skin penetration.

[0187] 3. In vitro skin penetration results

[0188] From Table 2 and Figure 7 It shows that at 36h, the skin permeation percentage of SIN-TGP in FAPEG-SNM@SIN-TGP NIR is about 7.36 times that of the original drug group. The cumulative skin percentage of SIN-TGP in FAPEG-SNM@SIN-TGP is about 3.20 times that of the original drug group. The skin permeation percentages of SIN-TGP in SNM@SIN-TGP NIR and SNM@SIN-TGP are 3.13 and 3.35 times that of the original drug group, respectively. It can be seen that the permeation percentage of SIN-TGP in the microneedle group is higher than that of the original drug group. Microneedles are a transdermal device that can overcome the barrier of the stratum corneum. Therefore, the cumulative release rate of the microneedle group is higher than that of the original drug group. Microneedles can effectively deliver drugs, improve the bioavailability of drugs, and can also effectively deliver nanoparticles to the subcutaneous tissue.

[0189] 4. Ex vivo skin retention results

[0190] Depend on Figure 8It can be seen that after the 36h transdermal test, except for the FAPEG-SNM@SIN-TGP group, the skin retention of the other groups was significantly higher than that of the original drug group. The drug retention in the skin of the FAPEG-SNM@SIN-TGP light-irradiated group after 36h was 2.49 times that of the original drug group; the drug retention in the skin of the SNM@SIN-TGP light-irradiated group was 4.35 times that of the original drug group. Among them, there was a significant difference between the skin retention of the two groups of light-irradiated preparations and the original drug group (P < 0.0001). The retention of the SNM@SIN-TGP light-irradiated group was 4.35 times that of the SNM@SIN-TGP group; the retention of the FAPEG-SNM@SIN-TGP light-irradiated group was 4.26 times that of the FAPEG-SNM@SIN-TGP group. Illumination can not only increase drug release, but also increase drug retention.

[0191] Table 2 In vitro skin permeation parameters of SIN-TGP in drug-loaded microneedles and original drug groups

[0192]

[0193]

[0194] Note: Compared with SIN-TGP solution group: ****P<0.0001, ***P<0.0001, the preparation name in the list represents the soluble microneedle loaded with the preparation

[0195] 5. Experimental results of delivery mechanism investigation

[0196] The results of the in vitro skin experiment showed that the microneedle group could significantly increase the penetration and retention of the drug. Near-infrared light irradiation could significantly increase the retention of the drug in the skin. The results of the in vivo fluorescence imaging experiment showed that FAPEG-silane modification could make the preparation accumulate at the site of inflammation and prolong the retention of the preparation in the joint cavity.

[0197] In addition, it should be noted that the names of the specific reagents and raw materials described in this specification may be different. All equivalent or simple changes made according to the principles and embodiments of the present invention are included in the protection scope of the present invention. Those skilled in the art of the present invention may make various modifications or supplements to the specific embodiments described or replace them in a similar manner, as long as they do not deviate from the structure of the present invention or exceed the scope defined by the claims, they should all fall within the protection scope of the present invention.

Claims

1. A photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis, characterized in that: The invention comprises the following components: 300-500 parts of silicon nanobottle modified with folic acid PEG, 3-4 parts of sinomenine hydrochloride, 12-16 parts of total glycosides of white paeony, 5-30 parts of perfluorohexane, 5-10 parts of indocyanine green, 100-200 parts of tetradecanol, and 1-10 parts of pure water; The method for preparing the photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis comprises the following steps: Step 1, preparing a silicon nanobottle by reacting (3-chloropropyl)trimethoxysilane and butyl orthosilicate; Step 2, reacting folic acid PEG-silane with the nanobottle to generate a folic acid PEG-modified silicon nanobottle; Step 3: 300-500 parts of folic acid PEG-modified silicon nanobottles are loaded with 3-4 parts of sinomenine hydrochloride, 12-16 parts of total glucosides of white peony, 100-200 parts of tetradecanol, 5-30 parts of perfluorohexane, and 5-10 parts of indocyanine green to obtain a photothermal drive motor loaded with sinomenine and total glucosides of white peony; Step 4: Evenly mix the photothermal driven motor containing sinomenine and total glucosides of white peony with the microneedle matrix and pour them into the microneedle mold, and dry them to obtain the photothermal driven motor microneedles containing sinomenine and total glucosides of white peony.

2. The method for preparing the photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to claim 1, characterized in that: The following steps are involved: Step 1, preparing a silicon nanobottle by reacting (3-chloropropyl)trimethoxysilane and butyl orthosilicate; Step 2, reacting folic acid PEG-silane with the nanobottle to generate a folic acid PEG-modified silicon nanobottle; Step 3: 300-500 parts of folic acid PEG-modified silicon nanobottles are loaded with 3-4 parts of sinomenine hydrochloride, 12-16 parts of total glucosides of white peony, 100-200 parts of tetradecanol, 5-30 parts of perfluorohexane, and 5-10 parts of indocyanine green to obtain a photothermal drive motor loaded with sinomenine and total glucosides of white peony; Step 4: Evenly mix the photothermal driven motor containing sinomenine and total glucosides of white peony with the microneedle matrix and pour them into the microneedle mold, and dry them to obtain the photothermal driven motor microneedles containing sinomenine and total glucosides of white peony.

3. The method for preparing a photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to claim 2, characterized in that: The volume ratio of (3-chloropropyl)trimethoxysilane to butyl orthosilicate is 1:10, the molecular weight of the folic acid PEG-silane is 2000, the weight ratio of the sinomenine hydrochloride, total glucosides of white paeony, tetradecanol, perfluorohexane, indocyanine green and folic acid PEG-modified silicon nanobottle is 0.4:1.6:20:50:1:40, and the concentration of the hyaluronic acid matrix is ​​100 mg / mL.

4. The method for preparing a photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to claim 2, characterized in that: The specific steps of preparing silicon nanobottles by reacting (3-chloropropyl)trimethoxysilane and butyl orthosilicate are as follows: Step 1, weigh a certain amount of polyvinyl pyrrolidone and dissolve it in n-pentanol, add citric acid ammonium solution and anhydrous ethanol, and vortex, wherein the citric acid ammonium solution is 0.2M citric acid ammonium solution prepared by dissolving 2.58 g of citric acid in ammonia water to 50 mL; Step 2: Add a certain amount of (3-chloropropyl)trimethoxysilane and butyl orthosilicate, vortex, then sonicate, and react under stirring at room temperature; Step 3: After the reaction is completed, centrifuge, wash with anhydrous ethanol, and dry to obtain a silicon nanobottle.

5. The method for preparing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to claim 2, characterized in that: The specific steps of reacting folic acid PEG-silane with nanobottle to form folic acid PEG-modified silicon nanobottle are as follows: Step 1, weigh a certain amount of the above silicon nanobottle and disperse it in a mixed solution of anhydrous ethanol and ammonia water; Step 2: In a 50°C water bath, add a folic acid PEG-silane solution dropwise and stir to react for 24 hours. The folic acid PEG-silane solution is prepared by dissolving 2 mg of folic acid PEG-silane in 2 mL of DMSO. Step 3: After the reaction is completed, wash with anhydrous ethanol and dry to obtain a silicon nanobottle modified with folic acid PEG.

6. The method for preparing the photothermal driven motor microneedle of sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to claim 2, characterized in that: The specific steps of loading sinomenine hydrochloride, total glucosides of white peony, tetradecanol, perfluorohexane, and indocyanine green into a silicon nanobottle modified with folic acid PEG to obtain a photothermal drive motor of sinomenine and total glucosides of white peony are as follows: Step 1, taking perfluorohexane and loading it into the above-mentioned folic acid PEG-modified silicon nanobottle by negative pressure; Step 2, add sinomenine hydrochloride, total glucosides of white paeony, indocyanine green, tetradecanol and methanol, and stir for 30 minutes; Step 3: Add pure water and centrifuge to wash, and then obtain the photothermal drive motor loaded with sinomenine and total glucosides of white paeony.

7. The method for preparing a photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to claim 6, characterized in that: Perfluorohexane is pre-treated with oxygen enrichment.

8. A method for preparing a photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to any one of claims 2 to 7, characterized in that: The steps of mixing the photothermal driven motor containing sinomenine and total glucosides of white peony with the microneedle matrix uniformly and pouring them into the microneedle mold and drying them to obtain the photothermal driven motor microneedle containing sinomenine and total glucosides of white peony are as follows: Step 1: Dissolve hyaluronic acid in appropriate amount of ultrapure water and let stand to defoam; Step 2: Add the above-mentioned photothermal driven motor containing sinomenine and total glucosides of white paeony into the hyaluronic acid solution and mix them evenly to obtain a drug-containing microneedle matrix; Step 3: Add the drug-containing microneedle matrix to the PDMS mold, evacuate the mold, remove bubbles and dry it to obtain the photothermal driven motor microneedles loaded with sinomenine and total glucosides of white paeony.

9. The method for preparing a photothermal driven motor microneedle containing sinomenine and total glucosides of white paeony for treating rheumatoid arthritis according to claim 8, characterized in that: The concentration of the hyaluronic acid solution was 100 mg / mL, the microneedle array of the microneedle PDMS mold was 10×10, and the needle tip length was 600 μm.

Citation Information

Patent Citations

  • Microneedle transdermal drug delivery paste for treating rheumatoid arthritis and preparation method of microneedle transdermal drug delivery paste

    CN109528695A

  • Gas-driven drug release nano motor for treating stomach diseases as well as preparation method and application of gas-driven drug release nano motor

    CN112190566A

  • Preparation method of photo-thermal self-driven material, preparation method of wearable device, delivery method of wearable device and application of wearable device

    CN115814079A

  • Photo-thermal responsive traditional Chinese medicine oxygen-carrying nano gas bomb as well as preparation method and application thereof

    CN116059183A

  • Microneedle array patch for drug delivery and production method thereof

    US20210322743A1